BioTek's Epoch Video Contest Winner Announced!
October 11, 2010
BioTek has declared a winner in their "Why I Need a BioTek Epoch For My Lab" video contest! Congratulations to Yener Selcuk, Matin Khan and Tim Kohrn, who work in a diagnostics laboratory in Lower Saxony, Germany.
Their video, "The New Lab" features a scientist's foray into a new laboratory, where he is unhappy performing manual, single spectrophotometric readings. He recognizes BioTek's Epoch Microplate Spectrophotometer as the solution to his problem, but his CEO, a reptilian character, denies the request. Luckily, the CEO has a change of heart, and everyone lives happily ever after.
"All the submitted videos were so creative; I hope the entrants had as much fun making the videos as we did watching them," noted Julie Murray, Marketing Communications Manager at BioTek. "Congratulations to the cast of "The New Lab" for a fantastic and entertaining combination of creativity and originality!"
The winners will receive BioTek's Epoch System, consisting of the monochromator-based Epoch Microplate Spectrophotometer, the unique Take3™ Multi-Volume Plate, and Gen5™ Data Analysis Software. Epoch provides outstanding performance from 200 nm to 999 nm for nucleic acid and protein quantification, wavelength scanning, end point, kinetic and well area scanning in 6- to 384-well microplates. The unique Take3 plate allows users to measure up to sixteen 2 µL samples, two BioCells™ or a standard cuvette. The Take3 interface in Gen5™ makes low volume nucleic acid quantification fast and easy with its pre-programmed protocols and data output.
Visit www.biotek.com/epochvideocontest to watch "The New Lab" and view other videos that received honorable mention.
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process and to enable cost-effective quantification of disease relevant molecules in the clinic.
For additional information, contact:
Chere Griffin, Account Executive
Shaw & Todd Advertising and Marketing Communications